QIAGEN Fully Acquires NeuMoDx Molecular Rounding Out Portfolio of PCR-Based Diagnostic Automation Systems
September 17, 2020 QIAGEN N.V. today announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248 million in cash. The move rounds out QIAGEN’s…